ArticleERJ open research2026
Effectiveness of mepolizumab on mucus plugs and clinical outcomes in severe eosinophilic asthma with and without coexisting bronchiectasis: a prospective pilot study.
Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mucus plugs (MPs) are common in severe eosinophilic asthma (SEA) and are often associated with airflow limitation and poor asthma control. MP formation is driven by type 2 (T2) inflammation and may be worsened by coexisting bronchiectasis (BE), a condition characterised by irreversible bronchial dilatation and mucus retention. The effect of mepolizumab on MP burden in SEA, either with or without BE, remains unclear. The objective of the present study was to evaluate the 12-month effectiveness of mepolizumab in reducing MP and improving clinical outcomes in SEA patients with high-resolution computed tomography (HRCT)-confirmed MP, stratified by the presence of BE. Methods: We prospectively analysed 47 SEA patients with HRCT-confirmed MPs treated with mepolizumab for 12 months. Patients were grouped into SEA+MP (n=26) and SEA+MP+BE (n=21). MPs were assessed using the Mucus Plug Score (MPS) and BE severity using the Bronchiectasis Severity Index (BSI). Clinical, functional and inflammatory parameters were evaluated pre and post treatment. Results: Mepolizumab significantly reduced MPS in both groups (-3 in SEA+MP (p=0.0005); -5 in SEA+MP+BE (p<0.0001)), improved Asthma Control Test (ACT) scores and reduced blood eosinophils and the number of annual exacerbations. Forced expiratory volume in 1 s (FEV Conclusion: Mepolizumab reduces MP burden and improves SEA outcomes; this is also the case when including patients with coexisting BE. MPs and BE may represent treatable, T2-driven traits that could serve as a therapeutic target in precision asthma care. These findings support the use of HRCT-derived MP assessment as a complementary biomarker to guide biologic therapy in SEA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.